SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for GERON CORP (GERN) (CIK 0000886744) (GERN) — Sep 10, 2020

GERON CORP (GERN) (CIK 0000886744)
Date: Sept. 10, 2020 · CIK: 0000886744 · Accession: 0000000000-20-008535

AI Filing Summary & Sentiment

File numbers found in text: 333-248637

Date
September 10, 2020
Author
Not clearly detected
Form
UPLOAD
Company
GERON CORP (GERN) (CIK 0000886744)

Letter

United States securities and exchange commission logo September 10, 2020 Olivia K. Bloom Chief Financial Officer Geron Corporation 919 East Hillsdale Boulevard, Suite 250 Foster City, CA 94404 Re:Geron Corporation Registration Statement on Form S-3 Filed September 4, 2020 File No. 333-248637 Dear Ms. Bloom: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Chad Mills, Esq.

Show Raw Text
United States securities and exchange commission logo
September 10, 2020
Olivia K. Bloom
Chief Financial Officer
Geron Corporation
919 East Hillsdale Boulevard, Suite 250
Foster City, CA 94404
Re:Geron Corporation
Registration Statement on Form S-3
Filed September 4, 2020
File No. 333-248637
Dear Ms. Bloom:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Chad Mills, Esq.